- Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints.
- Vutrisiran's improved dosing profile and tolerability are important positives, but the real value-driver is the HELIOS-B study in ATTR-cardiomyopathy, a much larger market.
- Recent setbacks with partner programs (a CRL for Leqvio and an amended protocol for fitusiran) are disappointing but manageable.
- Alnylam shares look undervalued below the mid-$160's, but 2021 may be a lighter year for thesis-changing positive developments.
For further details see:
Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis Program